Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.22 +3.01%

+$0.81 today

Market cap
$1.76B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 3.12M

Average 1.81M

Balance Sheet

Inspect the capital base behind the business.

Assets

$1.53B

FY 2025 · Annual

+1.9% YoY

Liabilities

$1.60B

FY 2025 · Annual

+29.3% YoY

Equity

-$73.00M

FY 2025 · Annual

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents307.58M132.94M213.58M173.73M434M
Short-term Investments432.61M614.82M363.63M436.3M259M
Net Receivables44.43M40.45M73.39M121.8M159M
Inventory16.23M26.77M33.97M45.01M52M
Other Current Assets55.75M68.93M47.62M40.29M47M
Total Current Assets856.6M883.9M732.18M817.12M951M
Property, Plant & Equipment (Net)176.18M259.73M290.57M265.93M267M
Goodwill44.41M44.41M44.41M44.41M44M
Intangible Assets130.79M160.11M166.27M178.31M176M
Long-term Investments293.86M148.97M199.9M135M59M
Tax Assets00000
Other Non-current Assets20.56M48.34M57.69M62.68M35M
Total Non-current Assets665.79M661.55M758.83M686.33M581M
Total Assets1.52B1.55B1.49B1.5B1.53B
Account Payables17.14M43.27M42.11M38.76M31M
Short-term Debt000081M
Tax Payables00000
Deferred Revenue7.61M1.48M000
Other Current Liabilities00142.79M87.47M183M
Total Current Liabilities181.37M261.21M280.44M344.15M384M
Long-term Debt00001.17B
Deferred Tax Liabilities33.31M31.67M30.06M30.06M30M
Deferred Revenue (Non-current)1.47M0000
Other Non-current Liabilities352.79M880.26M874.53M836.91M(4M)
Total Non-current Liabilities418.47M931.74M935.16M897.01M1.22B
Total Liabilities599.84M1.19B1.22B1.24B1.61B
Common Stock69K70K82K92K0
Retained Earnings(2.07B)(2.78B)(3.39B)(3.96B)(4.53B)
Accumulated OCI(1.4M)(6.57M)647K(643K)1M
Other Stockholders Equity00432K3.59M8M
Minority Interest0007M7M
Total Equity922.56M352.49M275.41M262.3M(73M)
Total Debt41.97M31.59M43.17M40.34M1.28B
Net Debt(265.61M)(101.35M)(170.42M)(133.39M)842M

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$175.0M
Short-term Investments$238.0M
Receivables$121.0M
Inventory$55.0M
Other Current$68.0M
Total Current Assets$657.0M
PP&E (Net)$239.0M
Goodwill$44.0M
Intangible Assets$174.0M
Long-term Investments$127.0M
Other Non-current$55.0M
Total Non-current Assets$639.0M
Total Assets$1.3B

Analysis

Selected assets total $1.3B for Latest. The largest visible component is PP&E (Net) at $239.0M, about 18.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 3, 2026
SC 13G/ASC 13G/A filingOct 30, 2026

How much cash does RARE have?

Ultragenyx Pharmaceutical Inc. (RARE) reported $434.00M in cash and equivalents in fiscal 2025.

How much debt does RARE carry?

Ultragenyx Pharmaceutical Inc. (RARE) reported $1.28B of total debt, with net debt of $842.00M.